Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Bernd Eisele"'
Autor:
Cyrill A. Rentsch, Piet Bosshard, Grégoire Mayor, Malte Rieken, Heike Püschel, Grégory Wirth, Richard Cathomas, Gerald P. Parzmair, Leander Grode, Bernd Eisele, Hitt Sharma, Manish Gupta, Sunil Gairola, Umesh Shaligram, Daniel Goldenberger, François Spertini, Régine Audran, Milica Enoiu, Simona Berardi, Stefanie Hayoz, Andreas Wicki
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Background: VPM1002BC is a modified mycobacterium Bacillus Calmette Guérin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC). The genetic modifications are expected to result in better immunogenicity and less side effects. We re
Externí odkaz:
https://doaj.org/article/435b8c0fec2b484c8e79c927de64db29
Autor:
Natalie E. Nieuwenhuizen, Prasad S. Kulkarni, Umesh Shaligram, Mark F. Cotton, Cyrill A. Rentsch, Bernd Eisele, Leander Grode, Stefan H. E. Kaufmann
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
The only licensed vaccine against tuberculosis (TB), bacille Calmette–Guérin (BCG), protects against severe extrapulmonary forms of TB but is virtually ineffective against the most prevalent form of the disease, pulmonary TB. BCG was genetically m
Externí odkaz:
https://doaj.org/article/5193cd2d8df6407d9c77f79913fb90bb
Autor:
Bernd Eisele, Martin Gengenbacher, Reginald Kidd, David McCown, Sheldon Morris, Steven Derrick, David Hokey, Dominick Laddy, Rosemary Chang, Megan Fitzpatrick, Leander Grode, Kamalakannan Velmurugan, Stefan H.E. Kaufmann, John Fulkerson, Michael J. Brennan
Publikováno v:
Vaccines, Vol 1, Iss 2, Pp 120-138 (2013)
The failure of current Mycobacterium bovis bacille Calmette–Guérin (BCG) vaccines, given to neonates to protect against adult tuberculosis and the risk of using these live vaccines in HIV-infected infants, has emphasized the need for generating ne
Externí odkaz:
https://doaj.org/article/0faed53a9b714acc8f5dbb8a8015cef0
Autor:
Daniel Goldenberger, Piet Bosshard, Heike Püschel, Bernd Eisele, Grégoire Mayor, Leander Grode, Grégory Johann Wirth, Andreas Wicki, Régine Audran, Richard Cathomas, Malte Rieken, Gerald P Parzmair, Cyrill A. Rentsch, François Spertini, Simona Berardi, Manish Gupta, Umesh Shaligram, Stefanie Hayoz, Hitt Sharma, Milica Enoiu, Sunil Gairola
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
OncoImmunology, Vol. 9, No 1 (2020) P. 1748981
Oncoimmunology
Rentsch, Cyrill A; Bosshard, Piet; Mayor, Grégoire; Rieken, Malte; Püschel, Heike; Wirth, Grégory; Cathomas, Richard; Parzmair, Gerald P; Grode, Leander; Eisele, Bernd; Sharma, Hitt; Gupta, Manish; Gairola, Sunil; Shaligram, Umesh; Goldenberger, Daniel; Spertini, François; Audran, Régine; Enoiu, Milica; Berardi, Simona; Hayoz, Stefanie; ... (2020). Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy. Oncoimmunology, 9(1), p. 1748981. Taylor & Francis 10.1080/2162402X.2020.1748981
OncoImmunology, Vol. 9, No 1 (2020) P. 1748981
Oncoimmunology
Rentsch, Cyrill A; Bosshard, Piet; Mayor, Grégoire; Rieken, Malte; Püschel, Heike; Wirth, Grégory; Cathomas, Richard; Parzmair, Gerald P; Grode, Leander; Eisele, Bernd; Sharma, Hitt; Gupta, Manish; Gairola, Sunil; Shaligram, Umesh; Goldenberger, Daniel; Spertini, François; Audran, Régine; Enoiu, Milica; Berardi, Simona; Hayoz, Stefanie; ... (2020). Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy. Oncoimmunology, 9(1), p. 1748981. Taylor & Francis 10.1080/2162402X.2020.1748981
Background: VPM1002BC is a modified mycobacterium Bacillus Calmette Guérin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC). The genetic modifications are expected to result in better immunogenicity and less side effects. We rep
Autor:
Gian D. van der Spuy, Anneke C. Hesseling, Jeroen Maertzdorf, Gerhard Walzl, Bernd Eisele, Mark F. Cotton, Julia K. Knaul, Andre G. Loxton, Hilary Johnstone, Stefan H. E. Kaufmann, Andrea Gutschmidt, Christiane Meller, Leander Grode
Publikováno v:
Clinical and Vaccine Immunology
Clinical and Vaccine Immunology : CVI
Clinical and Vaccine Immunology : CVI
Tuberculosis is a global threat to which infants are especially vulnerable. Effective vaccines are required to protect infants from this devastating disease. VPM1002, a novel recombinantMycobacterium bovisbacillus Calmette-Guérin (BCG) vaccine previ
Autor:
Mark F. Cotton, Stefan H. E. Kaufmann, Anneke C. Hesseling, Leander Grode, Gerhard Walzl, Bernd Eisele, Martin Gengenbacher
Publikováno v:
Expert Review of Vaccines; Vol 13
Tuberculosis remains a major health threat and vaccines better than bacillus Calmette-Guérin (BCG) are urgently required. Here we describe our experience with a recombinant BCG expressing listeriolysin and deficient in urease. This potential replace
Autor:
Christiane Brohm, Leander Grode, January Weiner, Bernd Eisele, Stefan H. E. Kaufmann, Christian A. Ganoza
Publikováno v:
Vaccine; Vol 31
Vaccine
Vaccine
Background Current vaccination using Mycobacterium bovis bacillus Calmette-Guerin (BCG), fails to prevent pulmonary tuberculosis (TB). New vaccination strategies are essential for reducing the global incidence of TB. We assessed the safety and immuno
Autor:
Bernd Eisele, Stefan H. E. Kaufmann, Silke Bandermann, Anca Dorhoi, Christiane Desel, Leander Grode
Publikováno v:
The Journal of Infectious Diseases
Journal of Infectious Diseases
Journal of Infectious Diseases
Background. New vaccines against tuberculosis (TB) are urgently needed because the only available vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG), fails to protect against pulmonary TB in adults. The recombinant Delta ureC hly+ BCG (rBCG)
Autor:
M. Enoui, G. Parzmair, G. Mayor, R. Audran, F. Spertini, R. Cathomas, S. Berardi-Vilei, A. Wicki, U. Shaligram, Grégory Johann Wirth, S. Hayoz, Leander Grode, C.A. Rentsch, P. Bosshard, Bernd Eisele, D. Goldenberger, Malte Rieken, H. Sharma, Heike Püschel
Publikováno v:
European Urology Supplements. 17:e1050
Autor:
Doris Beherens, Willem de Blok, Christian Wetterauer, Leander Grode, Bernd Eisele, Cyrill A. Rentsch, Joel R. Gsponer, Nicole van der Wel, Alexander Bachmann, Heike Püschel, Ankitha Minhas, Bas W.G. van Rhijn
Publikováno v:
Journal of Urology. 191
INTRODUCTION AND OBJECTIVES: The molecular profile of bladder cancer has been suggested to play a critical role in prognosis and treatment response. A greater understanding of the somatic mutations that arise, and co-exist, in advanced tumors could a